Final answer:
Ideal candidates for Mepolizumab (SC; IL-5 inhibitor) would be individuals with severe eosinophilic asthma.
Step-by-step explanation:
Ideal candidates for Mepolizumab (SC; IL-5 inhibitor) would be individuals with severe eosinophilic asthma. Mepolizumab is a medication that specifically targets and inhibits the activity of IL-5, a cytokine involved in the production and activation of eosinophils, which are white blood cells that play a role in inflammatory responses. It is indicated for use in patients with a history of multiple asthma exacerbations and elevated eosinophil levels despite standard asthma therapy.